摘要
目的：比较不同两种方法检测血清细胞角蛋白19片段（CYFRA21—1）对肺癌的临床诊断价值。方法：收集和本院患者的血清CYFRA21—1 ELISA方法；电化学发光法；检测结果及病理诊断，统计两段时期分别用ELISA和ECLIA方法检测CYFRA21-1对肺癌临床诊断的灵敏度和特异性。收集2008年2月～2008年5月本院57例因肺疾病入院的患者血清，同时采用ECLIA和ELISA方法检测血清CYFRA21-1，结合患者临床病理，观察高灵敏度方法出现低值阳性血清CYFRA21—1浓度的范围。结果：用ELISA方法检测血清CYFRA21—1对肺癌诊断的敏感度和特异性分别为：27．1％和97．8％，后期ECLIA法检测血清CYFRA21—1对肺癌诊断的敏感度和特异性分别为：83．6％和78．6％。同时用两种方法检测的57份患者标本中，有32份标本用两种方法检测血清CYFRA21-1均〈3．30ng／mL（阴性），13份标本用两种方法检测血清CYFRA21—1均≥3．30ng／mL（阳性），12份标本在ELISA方法中CYFRA21—1测定结果为阴性，而在ECLIA法中为阳性，浓度范围为（3．68—8．20）ng／mL，该12名患者中有9名经细胞学或组织病理学确诊为肺癌患者。结论：ECLIA法测定血清CYFRA21-1对肺癌的诊断比ELISA方法特异性稍低，但敏感度高很多，且能提示低值阳性（3．68—8．20ng／mL）血清CYFRA21-1浓度的肺癌患者，能更好地辅助临床对肺癌的早期诊断和疗效监测，
Objective： To compare the clinical value of cytokeratin-19-fragments （ CYFRA21-1 ） determination using electrochemilumineseence immunoassay （ECLIA） vs enzyme-linked immunosorbent assay （ELISA） in diagnosis of lung cancers. Methods： Data of serum CYFRA21-1 and pathologic diagnosis were collected from patients registered to our hospital between May 2005 and May 2007, and between October 2007 and May 2008, when modalities used to determine CYFRA21-1 during these two intervals were ELISA and ECLIA, respectively. Clinical sensitivity and specificity in diagnosis of lung cancer by ECLIA and ELISA were evaluated. Set-am samples of 57 patients admitted due to lung diseases between February 2008 and May 2008 were collected for determination of CYFRA21-1 using ECLIA and ELISA to investigate the range of low-level positive results with high-sensitivity method, as compared with clinical pathology. Results：The sensitivity and specificity in diagnosing lung cancer with CYFRA21-1 were 27.1% and 97.8% measured by ELISA, 83. 6% and 78. 6% measured by ECLIA. Among the 57 samples, 32 tested negative for CYFRA21-1 （CYFRA21-1 〈 3.30 ng/ml） and 13 tested positive （CYFRA21-1 ≥3.30 ng/ml） by both ECLIA and ELISA. 12 samples tested negative for CYFRA21-1 with ELISA but positive with ECLIA, within a concentration range between 3. 68 and 8. 20ng/ml. Nine out of the 12 patients were confirmed with lung cancer by cytology or histopathology. Conclusions： CYFHA21-1 measured by ECLIA appeared less specific but much more sensitive in diagnosis of lung cancer than by ELISA, and moreover, ECLIA can be effective to identify lung cancer with low but positive serum CYFRA21-1 （3.68 -8.20ng/ml）. Therefore, ECLIA may be more helpful for early diagnosis and efficacy monitoring in lung cancer.
出处
《广州医学院学报》
2010年第1期44-47,共4页
Academic Journal of Guangzhou Medical College
关键词
细胞角蛋白19片段
肺癌
电化学发光免疫分析
酶联免疫吸附试验
cytokeratin-19-fragments
lung cancer
electroehemilumineseenee immunoassay
enzyme-linked immunosorbent assay
